In this webinar, Dr. Kevin Ard discussed recent developments in the field of PrEP, such as licensure of long-acting injectable medication for HIV pre-exposure prophylaxis (PrEP), availability of a generic PrEP formulation, and concerns about the 340B program. These developments have led to questions about financing PrEP in 2023 and beyond. In this interactive session, experts on PrEP will discuss the current PrEP financing landscape and what may be in store for the future.
